Search This Blog

Thursday, November 14, 2019

FDA Ad Com thumbs up on CV benefit of Amarin’s Vascepa

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0 backing the cardiovascular (CV) benefit of Amarin’s (NASDAQ:AMRN) Vascepa (icosapent ethyl).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)